⌕
Seaport Therapeutics · SPTX · Nasdaq
Tenet — · insufficient data
Compare
$18.32+0.05%At close
$18.32+0.01 (+0.05%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Seaport Therapeutics (SPTX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is SPTX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Zacks Investment ResearchNov 5, 2026 · 10:56 ET
How Much Upside is Left in Seaport Therapeutics, Inc (SPTX)? Wall Street Analysts Think 77.91%

The mean of analysts' price targets for Seaport Therapeutics, Inc (SPTX) points to a 77.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i…

SPTX +0.1% todayRead at source ↗
● Business WireNov 2, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.…

SPTX +0.1% todayRead at source ↗
● Seeking AlphaOct 29, 2026 · 03:27 ET
Seaport Therapeutics: Borrowed Efficacy, Engineered Safety, And A Post-IPO Discount

Seaport Therapeutics leverages proprietary Glyph technology to enhance bioavailability and safety for CNS drugs, targeting MDD and GAD markets. SPTX maintains a cash runway into 2029, with $427.3 million at June 30, trad…

SPTX +0.1% todayRead at source ↗
● Business WireOct 9, 2026 · 13:00 ET
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress.…

SPTX +0.1% todayRead at source ↗
● Business WireOct 9, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company developing novel neuropsychiatric medicines, today announced the presentation of Phas…

SPTX +0.1% todayRead at source ↗
● Business WireOct 7, 2026 · 13:00 ET
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance.…

SPTX +0.1% todayRead at source ↗
● Business WireOct 7, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance

BOSTON--(BUSINESS WIRE)--Seaport Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder & Sleep Disturbance.…

SPTX +0.1% todayRead at source ↗
● Defense WorldOct 3, 2026 · 04:41 ET
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Up – Should You Buy?

Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) gapped up before the market opened on Thursday. The stock had previously closed at $18.69, but opened at $20.12. Seaport Therapeutics shares last traded at $19.…

SPTX +0.1% todayRead at source ↗
● Defense WorldOct 2, 2026 · 05:41 ET
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Down – What’s Next?

Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) shares gapped down before the market opened on Wednesday. The stock had previously closed at $19.64, but opened at $18.85. Seaport Therapeutics shares last trad…

SPTX +0.1% todayRead at source ↗
● Defense WorldSep 28, 2026 · 04:15 ET
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Consensus Target Price of $38.57

Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve brokerages that are presently covering the firm, MarketBeat.com reports. Two equities …

SPTX +0.1% todayRead at source ↗
● Business WireSep 14, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Seaport Therapeutics to Participate in September Investor Conferences

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced th…

SPTX +0.1% todayRead at source ↗
● Seeking AlphaSep 9, 2026 · 16:17 ET
Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

SPTX +0.1% todayRead at source ↗
● Business WireSep 9, 2026 · 13:13 ET
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers.…

SPTX +0.1% todayRead at source ↗
● Business WireSep 9, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers.…

SPTX +0.1% todayRead at source ↗
● 247 WallstAug 20, 2026 · 10:40 ET
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those…

SPTX +0.1% todayRead at source ↗

No upcoming events in the feeds.

ANT24−6.6%
NVDA7−2.3%
FOX6−2.9%
AMD3−6.0%

Article counts from the last market-wide feed page, across every symbol we track and not just SPTX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.